title: A long-term follow-up analysis in adult acute myeloid leukemia patients after hematopoietic stem cell transplantation.
abstract: OBJECTIVE
  Over the last 17 years, 119 adult acute myeloid leukemia patients have undergone hematopoietic stem cell transplantation at our Center.
  
  
  METHODS
  Seventy patients in first complete remission received hematopoietic stem cell transplantation (28 allogeneic and 42 autologous HSCT) as late intensification after conventional chemotherapy; 38 patients received allogeneic hematopoietic stem cell transplantation in a more advanced phase. A reference group was built up by collecting 40 acute myeloid leukemia patients who received high-dose cytosine arabinoside as late intensification and whose complete remission lasted more than 10 months.
  
  
  RESULTS
  Results of the study led to conclude that an earlier timing of allogeneic hematopoietic stem cell transplantation can be recommended in order to treat patients who would otherwise suffer an early relapse.
  
  
  CONCLUSIONS
  The outcome of autologous hematopoietic stem cell transplantation in patients not in first complete remission supports the possibility of achieving good quality second complete remissions and suggests that autografting may be a life-saving strategy in selected acute myeloid leukemia patients with advanced disease.
authors.affiliation: Ematologia I, Centro Trapianti di Midollo, Fondazione Ospedale Maggiore e Università degli Studi di Milano, Italy.
authors.forename: Claudio
authors.initials: C
authors.lastname: Annaloro
authors.forename: Vittorio Ruggero
authors.initials: VR
authors.lastname: Zilioli
authors.forename: Nicola Stefano
authors.initials: NS
authors.lastname: Fracchiolla
authors.forename: Claudia
authors.initials: C
authors.lastname: Vener
authors.forename: Davide
authors.initials: D
authors.lastname: Soligo
authors.forename: Aldo
authors.initials: A
authors.lastname: Della Volpe
authors.forename: Giorgio Lambertenghi
authors.initials: GL
authors.lastname: Deliliers
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D002648:Child; D003561:Cytarabine / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000601:surgery*; D015993:Life Tables; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D016019:Survival Analysis; D013997:Time Factors; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D003561:Cytarabine